Oculis (NASDAQ:OCS) Trading 4% Higher – Should You Buy?

Oculis Holding AG (NASDAQ:OCS) rose 4% during mid-day trading on Thursday . The stock traded as high as $19.34 and last traded at $19.49. Approximately 34,697 shares traded hands during trading, a decline of 24% from the average daily volume of 45,579 shares. The stock had previously closed at $18.74.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Robert W. Baird increased their target price on Oculis from $37.00 to $41.00 and gave the stock an “outperform” rating in a report on Thursday, March 13th. Chardan Capital reissued a “buy” rating and issued a $28.00 target price on shares of Oculis in a report on Thursday, March 13th. Finally, HC Wainwright cut their target price on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th.

Oculis Stock Down 0.4 %

The company has a market cap of $854.47 million, a price-to-earnings ratio of -10.14 and a beta of 0.01. The company has a current ratio of 4.02, a quick ratio of 4.02 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $20.95 and a 200-day simple moving average of $17.18.

Oculis (NASDAQ:OCS) last announced its earnings results on Tuesday, March 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. As a group, analysts predict that Oculis Holding AG will post -2.09 EPS for the current year.

Institutional Trading of Oculis

A number of hedge funds and other institutional investors have recently modified their holdings of OCS. abrdn plc boosted its stake in Oculis by 23.0% during the fourth quarter. abrdn plc now owns 1,009,424 shares of the company’s stock valued at $17,150,000 after buying an additional 188,871 shares in the last quarter. Bank of America Corp DE lifted its holdings in Oculis by 58.2% in the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock valued at $493,000 after acquiring an additional 10,667 shares during the last quarter. Citadel Advisors LLC bought a new position in shares of Oculis during the 4th quarter valued at about $389,000. Bellevue Group AG acquired a new position in shares of Oculis in the 4th quarter worth approximately $170,000. Finally, Geode Capital Management LLC raised its holdings in shares of Oculis by 12.0% in the 4th quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after purchasing an additional 1,800 shares in the last quarter. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.